Swiss researchers create artificial lung to study Covid-19 blood clots
A Belgian doctor studies an x-ray of the lungs of a patient who is suspected of having Covid-19, March 24, 2020
Keystone / Stephanie Lecocq
Scientists at the Federal Institute of Technology Lausanne (EPFL) have created an artificial lung to better understand how the new coronavirus causes blood clots in certain patients.
This content was published on
3 minutes
EPFL/sb
Português
pt
Pesquisadores suíços criam pulmão artificial para estudar coágulos de sangue de Covid-19
A recent studyExternal link revealed that around 10% of hospitalised Covid-19 patients develop blood clots, however, it is unclear why the virus causes this reaction. In the most severe cases, the blood clots can result in a stroke.
To investigate this phenomenon and other Covid-19 infections, EPFL scientists have developed a microfluidic chip that models the human lung and replicates part of its structure.
The chip holds lung epithelial cells, blood-vessel cells and immune-system cells, and lets scientists directly observe how the virus attacks human cells and triggers the formation of blood clots.
When that happens, scientists say two mechanisms may be occurring. One is an excess production of cytokines, which are proteins that play a role in immune-cell signalling, leading to so-called “cytokine storms”. These can damage blood vessels and cause blood clots to form, and are potentially fatal.
The other possible reason is damage to the interior lining of blood vessels – or the endothelium – in the lungs. The lungs have a lot of this kind of tissue, and when it’s damaged, blood can coagulate easily and form clots.
Lung-on-a-chip
To help find out, the EPFL team took a lung-on-a-chip device and adapted it to model the individual steps in a SARS-CoV-2 attack on the lungs. The device contains microfluidic channels that feed nutrients to cells on the chip, which are arranged to recreate a section of the lungs.
Inside the chip there is a layer of epithelial cells, the cells coating the lungs, and a layer of endothelial cells, the cells lining the blood vessels. These two layers are separated by a membrane.
During their tests, when the virus was introduced into their device it first attacked the outside layer of epithelial cells, just like in a natural infection. The team found that within a day the virus had reached the inner layer of endothelial cells and caused considerable damage over subsequent days.
“There was enough damage to destroy the endothelium and expose blood in the vessels to air, causing clots to form,” says Vivek Thacker, a postdoctoral researcher. “With our lung-on-a-chip system, we found that the virus may be causing blood clots by attacking the endothelium directly. However, that doesn’t mean that cytokines don’t play a role too and make things worse.”
To further their understanding, the team plan to use their lung-on-a-chip with actual blood samples so that they can observe clot formation directly.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
This content was published on
By 8am on Saturday, an 11-kilometre queue had formed at the Gotthard tunnel’s northern entrance, with drivers facing nearly two hours of delays.
Plant-based meat market in Switzerland set to grow to CHF361 million by 2030
This content was published on
Switzerland’s market for plant-based meat alternatives has a potential value of around CHF 242 million this year, though it remains a niche market.
This content was published on
The army is looking for a modern solution for its decommissioned fortress mortar bunkers, with plans to turn them into hardened defence hubs.
This content was published on
Spain ended Switzerland’s run in the Women’s Euros on Friday, but fans in Bern made history with the largest supporters’ march in Women’s Euros history.
This content was published on
Solar energy pioneer Raphaël Domjan and his team continued preparations for the altitude record attempt at 10,000 metres with the SolarStratos solar aircraft.
This content was published on
Cattle in the canton of Geneva and in the neighbouring region of Terre Sainte in the canton of Vaud are being vaccinated against the contagious viral skin nodule disease. The first cases of the animal disease were reported at the end of June in France, just outside Geneva.
Fewer attacks on Swiss ATMs but their future remains uncertain
This content was published on
Bank ATMs in Switzerland are less prone to attacks by criminals, but their future remains uncertain given the less active use of cash by the population.
This content was published on
A series of rockfalls occurred above the village of Brienz between 9 and 12 July. According to the municipality of Albula, the overall situation remains tense. Several people disregarded the ban on entering the area around the village.
This content was published on
Arosa Bergbahnen achieved the highest figure in its 95-year history in the 2024/25 financial year with net revenue of CHF 37 million. Arosa Lenzerheide was able to capitalise on strengths such as snow reliability and the size of the ski area in a long winter season, the company announced on Thursday.
Swiss factory rushes to prepare for Moderna Covid-19 vaccine
This content was published on
Workers are racing to set up production lines at the Lonza factory in Visp to be able to start making a vaccine for US firm Moderna later this year.
Virologist calls for more tests, masks for children
This content was published on
Geneva virologist Isabella Eckerle has called for more testing and obligatory mask wearing for younger children at school.
Lausanne hospital test chosen for coronavirus study
This content was published on
A test developed at Lausanne university hospital has been chosen for wide-scale coronavirus antibody studies of the Swiss population.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.